Preview: Mirum Pharmaceuticals's Earnings
Portfolio Pulse from Benzinga Insights
Mirum Pharmaceuticals (NASDAQ:MIRM) is scheduled to release its quarterly earnings report on February 28, 2024. Analysts predict an EPS of $-0.24. The company's past performance shows a mixed reaction to earnings reports, with the stock price fluctuating based on actual EPS versus estimates and guidance provided. Shares are currently trading at $29.06, reflecting a 22.91% increase over the last 52 weeks. Investors are optimistic but will be closely watching the guidance for future growth.
February 27, 2024 | 6:01 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Mirum Pharmaceuticals is anticipated to report an EPS of $-0.24 for the upcoming quarter. Historical data shows stock price sensitivity to earnings outcomes and guidance. Currently trading at $29.06, the stock has seen a 22.91% increase over the past year.
The expected EPS and historical performance suggest a cautious outlook for MIRM's short-term stock price movement. The stock has shown sensitivity to both earnings outcomes and forward guidance, indicating that the upcoming earnings report could have a significant impact. However, the positive year-to-date performance and the company's ability to beat past EPS estimates may temper any negative reactions, leading to a neutral score.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100